Tiger BioSciences Showcases Clinical Breakthroughs and Future Innovations
Following substantial investment in research for the year, Tiger BioSciences has made impressive strides in the field of wound care. This has not only reinforced its leading status in the industry but also set the stage for further advancements as we approach 2026. The company's focus on evidence-based research underscores its commitment to developing effective solutions that are scientifically validated.
Commitment to Quality Research and Development
In 2025, Tiger BioSciences successfully supported five peer-reviewed retrospective clinical studies, with two concentrated on its flagship product, completeFT. These studies affirm the product's efficacy in advanced wound management, establishing it as a reliable option for healthcare professionals across the country.
Innovative Approaches to Wound Care
Furthermore, the company has embarked on a prospective, randomized controlled trial (RCT) to assess the effectiveness of caregraFT in treating diabetic foot ulcers and venous leg ulcers. Preliminary results from this ongoing trial have indicated encouraging clinical outcomes, highlighting caregraFT as a promising option for chronic wound treatment.
Leadership Insights on Clinical Evidence
Garrett Grinsfelder, President of Tiger Wound Care, articulated the company's philosophy succinctly: "We believe that meaningful clinical evidence is the foundation of long-term innovation in wound care." This commitment is reflected in Tiger BioSciences' strategic investments aimed at producing trustable, data-driven products for clinicians.
Looking Ahead to Future Research Projects
As part of its ongoing efforts, Tiger BioSciences is poised to broaden its clinical research initiatives in the coming years. This includes launching another RCT to evaluate caregraFT's effectiveness specifically in pressure ulcer care. The progressive research agenda aims to further enrich the existing portfolio of evidence supporting their innovative products.
Product Validation and Clinical Data
With multiple peer-reviewed studies and manuscripts finalized, along with two active RCTs slated to continue into 2026, Tiger BioSciences stands at a significant advantage in the market. As Mr. Grinsfelder noted, the company boasts a range of offerings substantiated by solid clinical and scientific data, setting them apart from competitors.
About Tiger BioSciences
Tiger BioSciences operates as a vertically integrated cell and tissue technology firm that is deeply involved in the recovery, processing, development, research, and distribution of a variety of cellular, acellular, and matrix-like products. As a tissue recovery agency and processing innovator, the company is dedicated to serving patients, healthcare providers, and donor families with its advanced solutions.
Frequently Asked Questions
What recent achievements has Tiger BioSciences highlighted?
Tiger BioSciences has showcased major clinical and scientific milestones resulting from its investments in evidence-based research throughout 2025.
What is the focus of the new clinical research by Tiger BioSciences?
The company plans to evaluate caregraFT's effectiveness specifically for pressure ulcer care through upcoming randomized controlled trials.
How does Tiger BioSciences ensure product effectiveness?
The firm emphasizes rigorous clinical trials and peer-reviewed studies to substantiate the efficacy and safety of its products.
Who leads the research initiatives at Tiger BioSciences?
Garrett Grinsfelder, the President of Tiger Wound Care, plays a pivotal role in guiding the company's research directions and strategies.
What is the vision of Tiger BioSciences for future patient care?
Tiger BioSciences aims to continue delivering innovative products backed by clinical evidence to improve patient care in wound management.
